News
People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...
The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations.
Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...
Novo Nordisk A/S is hunting for more early-stage deals to pad its pipeline of next-generation obesity drugs, as the drugmaker ...
Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback